acetaminophen and Contusions studies

Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Research Excerpts

Excerpt	Relevance	Reference
"To compare acetaminophen extended release 1,300 mg 3 times daily and ibuprofen 400 mg 3 times daily for treatment of signs and symptoms of grade I or II lateral ankle sprains."	9.12	Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. ( Dalton, JD; Schweinle, JE, 2006)
"To compare acetaminophen extended release 1,300 mg 3 times daily and ibuprofen 400 mg 3 times daily for treatment of signs and symptoms of grade I or II lateral ankle sprains."	5.12	Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. ( Dalton, JD; Schweinle, JE, 2006)
"Optimizing postoperative pain control is an important aspect in perioperative patient care."	2.71	Pre-incision infiltration of local anesthetic reduces postoperative pain with no effects on bruising and wound cosmesis after thyroid surgery. ( Bagul, A; Brook, NR; Metcalfe, MS; Nicholson, ML; Taha, R, 2005)
"Acute soft tissue injuries are common and costly."	2.66	Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. ( Dalziel, SR; Jones, P; Lamdin, R, 2020)
" The evidence was usually either low quality or very low quality, reflecting study limitations, indirectness such from as suboptimal dosing of single comparators, imprecision, or one or more of these."	2.52	Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. ( Dalziel, SR; Frampton, C; Jones, P; Lamdin, R; Miles-Chan, JL, 2015)

Research

Studies (10)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (30.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (40.00)	29.6817
2010's	2 (20.00)	24.3611
2020's	1 (10.00)	2.80

Authors	Studies
Jones, P	2
Lamdin, R	2
Dalziel, SR	2
Miles-Chan, JL	1
Frampton, C	1
Kan, E	1
Coelho, MS	1
Reside, J	1
Card, SJ	1
Tawil, PZ	1
Mahler, P	1
Mahler, F	1
Duruz, H	1
Ramazzina, M	1
Liguori, V	1
Mautone, G	1
Rahusen, FT	1
Weinhold, PS	1
Almekinders, LC	1
Bagul, A	1
Taha, R	1
Metcalfe, MS	1
Brook, NR	1
Nicholson, ML	1
Dalton, JD	1
Schweinle, JE	1
Abbott, CJ	1
Bouchier-Hayes, TA	1
Hunt, HA	1
Aleixo, PL	1
Monteiro, PR	1
da Silva, AC	1
Wardle, EN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, 7-Day Study of the Efficacy and Safety of Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome[NCT00140933]	Phase 3	274 participants	Interventional	2003-04-30	Terminated
Efficacy and Security of Combined Analgesia (Opioid and Anti-inflammatory Agent) to Control Pain in Children Seen in the Emergency Department for a Trauma of a Limb[NCT01189773]	Phase 4	200 participants (Actual)	Interventional	2008-02-29	Completed
An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain[NCT00446797]	Phase 4	278 participants (Actual)	Interventional	2007-05-31	Completed
Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting[NCT01827475]	Phase 2	90 participants (Actual)	Interventional	2010-07-31	Completed
The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Liga[NCT00954785]	Phase 4	0 participants (Actual)	Interventional	2009-11-30	Withdrawn (stopped due to The study was terminated by Merck USA. The company did not supply drugs for the study.)
A Randomized, Double-Blind, Parallel-Group Study Comparing the Safety and Effectiveness of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Ankle Sprains.[NCT00261560]	Phase 4	260 participants (Actual)	Interventional		Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Assessment of ankle pain by VAS: 100 mm horizontal line with left end being No Pain & right end being Worst Possible Pain. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at day 3 minus mean score at baseline" (NCT00446797)
Timeframe: Baseline and day 3

Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population

Intervention	scores on a scale (Mean)
Celecoxib	-44.88
nsNSAIDs	-40.76

"Assessment of ankle pain by VAS: 100 mm horizontal line, left end being No Pain & right end being Worst Possible Pain. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at observation minus mean score at baseline" (NCT00446797)
Timeframe: Baseline and days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Index

Intervention	scores on a scale (Mean)
	Day 2	Day 3	Day 7
Celecoxib	-29.25	-44.87	-61.17
nsNSAIDs	-25.98	-40.75	-57.89

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~The pain interference index is the average of pain interference questions 5A to 5G. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5A

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	4.07	2.79	1.28
nsNSAIDs	4.01	2.83	1.33

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5B

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.40	3.65	1.78
nsNSAIDs	5.37	4.07	1.90

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5C

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.72	2.43	1.17
nsNSAIDs	3.64	2.38	1.26

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5D

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.10	3.58	1.65
nsNSAIDs	5.11	3.69	1.62

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5E

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.29	4.04	1.84
nsNSAIDs	5.39	4.04	1.87

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5F

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	2.70	1.81	0.80
nsNSAIDs	2.67	1.69	0.78

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5G

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	2.97	1.90	0.68
nsNSAIDs	2.87	1.86	0.82

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.33	2.13	1.07
nsNSAIDs	2.99	2.06	1.10

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Pain severity index is the average of the pain severity questions 1 to 4. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	4.24	2.84	1.37
nsNSAIDs	4.48	3.26	1.68

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q1: Subject response to 'describe your pain at its worst in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 1, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.71	3.81	2.08
nsNSAIDs	5.90	4.44	2.38

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q2: Subject response to 'describe your pain at its least in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3

Intervention	scores on a scale (Mean)
	Day 2 (N = 133, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.25	2.07	0.83
nsNSAIDs	3.36	2.40	1.16

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q3: Subject response to 'describe your pain on the average'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	4.34	2.90	1.41
nsNSAIDs	4.41	3.26	1.74

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q4: Subject response to 'how much pain you have right now'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Number of Subjects Responding (Improving) - MITT Population

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N =135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.64	2.58	1.14
nsNSAIDs	4.23	2.92	1.43

The number of subjects showing a response: a decrease of at least 20 mm (that is improvement) on the pain visual analog scale (VAS) scale (NCT00446797)
Timeframe: Days 2, 3 and 7

Pain Relief - MITT Population

Intervention	participants (Number)
	Day 2 - response (N=134, 133)	Day 2 - no response	Day 3 - response (N=135, 131)	Day 3 - no response	Day 7 - response (N=133, 125)	Day 7 - no response
Celecoxib	91	43	124	11	129	4
nsNSAIDs	79	54	116	15	120	5

"Subject's response to the statement My relief from starting pain is. Scale from 0 = None to 4 = Complete." (NCT00446797)
Timeframe: Days 2, 3 and 7

Physician Global Assessment of Ankle Injury

Intervention	participants (Number)
	Day 2 - None (N=135, 132)	Day 2 - A little	Day 2 - Some	Day 2 - A lot	Day 2 -Complete	Day 3 - None (N=135, 131)	Day 3 - A little	Day 3 - Some	Day 3 - A lot	Day 3 -Complete	Day 7 - None (N=133, 125)	Day 7 - A little	Day 7 - Some	Day 7 - A lot	Day 7 -Complete
Celecoxib	8	25	49	52	1	0	15	33	84	3	1	6	7	77	42
nsNSAIDs	5	33	52	42	0	1	21	46	60	3	1	3	15	80	26

Investigator evaluation of overall severity of ankle injury. Scale: 5 point from 1 = Very mild (very mild signs and symptoms of ankle sprain) to 5 =Very severe (very severe signs and symptoms of ankle sprain) (NCT00446797)
Timeframe: Days 3 and 7

Subject Assessment of Normal Function / Activity

Intervention	participants (Number)
	Day 3 - very mild (N=134, 131)	Day 3 - mild	Day 3 - moderate	Day 3 - severe	Day 3 - very severe	Day 7 - very mild (N=132, 125)	Day 7 - mild	Day 7 - moderate	Day 7 - severe	Day 7 - very severe
Celecoxib	20	71	40	2	1	87	38	7	0	0
nsNSAIDs	12	79	38	2	0	70	47	7	1	0

"Subject response to question: How does your ankle injury affect your walking and normal activity? Scale from 1 = Normal walking/activity and no pain to 5 = Severely restricted walking due to pain and can't resume normal activities (normal activities defined as all activity that a subject did on a routine basis, including work and recreation)" (NCT00446797)
Timeframe: Days 2, 3 and 7

Subject's Global Assessment of Ankle Injury

Intervention	participants (Number)
	Day 2 - normal no pain (N =135, 133)	Day 2 - normal with pain	Day 2 - mildly restricted	Day 2 - moderately restricted	Day 2 - severely restricted	Day 3 - normal no pain (N = 135, 131)	Day 3 - normal with pain	Day 3 - mildly restricted	Day 3 - moderately restricted	Day 3 - severely restricted	Day 7 - normal no pain (N = 133, 125)	Day 7 - normal with pain	Day 7 - mildly restricted	Day 7 - moderately restricted	Day 7 - severely restricted
Celecoxib	5	40	59	19	12	18	52	49	14	2	62	55	11	4	1
nsNSAIDs	2	30	55	39	7	13	46	57	11	4	43	68	8	3	3

"Subject response to question: Considering all the ways your ankle injury affects you, how are you doing today? Scale: 5 point from 1 = very good (no symptoms and no limitation of normal activities) to 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)." (NCT00446797)
Timeframe: Days 2, 3 and 7

Need for Rescue Pain Relief

Pain Severity

Intervention	participants (Number)
	Day 2 - Very good (no symptoms) (N=135, 133)	Day 2 - Good (mild symptoms)	Day 2 - Fair (moderate symptoms)	Day 2 - Poor (severe symptoms)	Day 2- Very poor (very severe symptoms)	Day 3 - Very good (no symptoms) (N=135, 131)	Day 3 - Good (mild symptoms)	Day 3 - Fair (moderate symptoms)	Day 3 - Poor (severe symptoms)	Day 3 - Very poor (very severe symptoms)	Day 7 - Very good (no symptoms) (N=133, 125)	Day 7 - Good (mild symptoms)	Day 7 - Fair (moderate symptoms)	Day 7 - Poor (severe symptoms)	Day 7 - Very poor (very severe symptoms)
Celecoxib	1	40	76	17	1	8	68	54	5	0	53	61	17	2	0
nsNSAIDs	1	31	80	19	2	6	55	63	7	0	37	63	21	4	0

Intervention	participants (Number)
Ibuprofen	11
Acetaminophen	10
Ibuprofen-acetaminophen Combination	5

Pain score on 100 mm VAS from 0 (no pain) to 100 (worst pain) (NCT01827475)
Timeframe: 1 hour

Article	Year
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2015, Jul-01, Issue:7 Topics: Acetaminophen; Acute Disease; Administration, Oral; Analgesics; Analgesics, Opioid; Anti-Inflammator	2015

Article	Year
Periapical Microsurgery: The Effects of Locally Injected Dexamethasone on Pain, Swelling, Bruising, and Wound Healing. Journal of endodontics, 2016, Volume: 42, Issue:11 Topics: Acetaminophen; Adrenal Cortex Hormones; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthe	2016
Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions. Drugs under experimental and clinical research, 2003, Volume: 29, Issue:1 Topics: Acetaminophen; Administration, Topical; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Ankle Inj	2003
Pre-incision infiltration of local anesthetic reduces postoperative pain with no effects on bruising and wound cosmesis after thyroid surgery. Thyroid : official journal of the American Thyroid Association, 2005, Volume: 15, Issue:11 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Local; Anesthetics,	2005
Randomized controlled noninferiority trial to compare extended release acetaminophen and ibuprofen for the treatment of ankle sprains. Annals of emergency medicine, 2006, Volume: 48, Issue:5 Topics: Acetaminophen; Analgesics, Non-Narcotic; Ankle Injuries; Arthralgia; Contusions; Double-Blind Method	2006
A comparison of the efficacy of naproxen sodium and a paracetamol/dextropropoxyphene combination in the treatment of soft-tissue disorders. British journal of sports medicine, 1980, Volume: 14, Issue:4 Topics: Acetaminophen; Adult; Athletic Injuries; Clinical Trials as Topic; Contusions; Dextropropoxyphene; D	1980

Article	Year
Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. The American journal of sports medicine, 2004, Volume: 32, Issue:8 Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Stero	2004
[Clinical observations and analgesic properties of the association of paracetamol and phenylbutazone]. Revista brasileira de medicina, 1966, Volume: 23, Issue:9 Topics: Acetaminophen; Back Pain; Contusions; Ear Diseases; Headache; Humans; Joint Diseases; Muscular Disea	1966
Fibrinogen in liver disease. Archives of surgery (Chicago, Ill. : 1960), 1974, Volume: 109, Issue:6 Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Cholangitis; Cholestasis; Contusions; Endotox	1974

acetaminophen and Contusions